Objective To investigate theclinical efficacy of tiotropium combined with montelukast for elderly people with moderate bronchial asthma.Methods 103 elderly patients over 60 years old with moderate bronchial asthma selected from October 2012 to November 2015 were randomly divided into two groups.The control group(52 cases) received flixotide(125 μg,bid) + montelukast(10 mg·d-1).The observation group (51 cases) was given flixotide(125 μg,bid) + montelukast(10 mg·d-1) + tiotropium(18 μg·d-1).Clinical symptoms and lung function of the patients were determined for four weeks.Results At second week and fourth week,FEV1 and PEF of two groups were significantly improved to compare with pre-treatment (P<0.05),and the improvement rate of observation group was higher than control group (P<0.05);Compared with pre-treatment,symptoms scores of two groups were significantly improved in the daytime or at night(P<0.05).At night,the symptoms score of treatment group was obviously lower than control group(P<0.05).Conclusions Combination of tiotropium with montelukast in to treat moderate bronchial asthma in elderly were more effective,whichshould be promoted in clinical.%目的 探讨老年支气管哮喘病人行噻托溴铵联合孟鲁司特药物治疗的疗效.方法 2012年10月-2015年11月就诊的103例60岁以上中度支气管哮喘病人被分为两组,对照组(n=52)病人接受辅舒酮(早晚各1次,1次125μg)和孟鲁司特咀嚼片(每天1次,1次10mg)治疗;观察组(n=51)病人接受辅舒酮(早晚各1次,1次125μg)、孟鲁司特咀嚼片(每天1次,1次10mg)和噻托溴铵(每天1次,1次18μg)治疗,比较治疗前及治疗后4周病人症状评分及肺功能状况.结果 在各时间点,治疗前和治疗后比较对照组和观察组病人的肺功能指标第1 秒用力呼气容积(FEV1)和呼气峰流速(PEF)均得到了显著提高(P<0.05),且观察组提高幅度明显高于对照组;在治疗后,观察组和对照组日间和夜间的症状评分得到了显著改善(P<0.05),且观察组夜间临床症状改善优于对照组(P<0.05).结论 噻托溴铵、孟鲁司特联合用药可使中度老年支气管哮喘病人的临床症状、肺功能状态得到改善,值得临床推广使用.
展开▼
